These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32683851)

  • 21. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
    Hasby EA; Saied EM
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
    Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
    Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC).
    Shamaa AA; Zyada MM; Wagner M; Awad SS; Osman MM; Abdel Azeem AA
    Diagn Pathol; 2008 Nov; 3():45. PubMed ID: 19021895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of Topoisomerase II in female breast cancer.
    Koren R; Rath-Wolfson L; Ram E; Itzhac OB; Schachter B; Klein B; Gal R; Dreznik Z
    Oncol Rep; 2004 Oct; 12(4):915-9. PubMed ID: 15375522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using specific cytotoxics with a targeted mind.
    Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
    Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of DNA topoisomerase II-α: Clinical significance in laryngeal carcinoma.
    Feng Y; Zhang H; Gao W; Wen S; Huangfu H; Sun R; Bai W; Wang B
    Oncol Lett; 2014 Oct; 8(4):1575-1580. PubMed ID: 25202370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
    Martin-Richard M; Muñoz M; Albanell J; Colomo L; Bellet M; Rey MJ; Tabernero J; Alonso C; Cardesa A; Gascon P; Fernandez PL
    Oncology; 2004; 66(5):388-94. PubMed ID: 15331926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
    Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
    Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
    Durbecq V; Paesmans M; Cardoso F; Desmedt C; Di Leo A; Chan S; Friedrichs K; Pinter T; Van Belle S; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Perren TJ; Leroy JY; Rouas G; Sotiriou C; Piccart M; Larsimont D
    Mol Cancer Ther; 2004 Oct; 3(10):1207-14. PubMed ID: 15486187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Combined Clinical Diagnosis of TNF-
    Jiang J; Zhang W; Liu H; Yang Y; Zhang W; Zang C
    J Oncol; 2022; 2022():4885378. PubMed ID: 35783155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression levels and clinical values of miR-92b-3p in breast cancer.
    Du Y; Miao Z; Wang K; Lv Y; Qiu L; Guo L
    World J Surg Oncol; 2021 Aug; 19(1):239. PubMed ID: 34380511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.